profit from every $100 of sales.
$0$100
Upstream Bio
$3.58+10.84% today
-84.4% in 1 year
1-year low $2.741-year high $32.60
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Upstream Bio sold, what it kept, and what it did with the cash.
Sales went from $1.21 million in 2022 to $2.85 million in 2025, with -$143 million of profit last year.
SalesProfit
Upstream Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Upstream Bio | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Upstream Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 2 | 2 | 3 | |
| – | – | – | – | |
| -24 | -40 | -78 | -160 | |
| -24 | -40 | -78 | -160 | |
| -24 | -21 | -63 | -143 | |
| -0.66 | -1.05 | -1.17 | -2.64 | |
| – | – | – | – | |
| -1,972.7% | -1,685.5% | -3,281.2% | -5,618.8% | |
| -1,969.3% | -862.9% | -2,650.0% | -5,026.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 18 | 117 | 482 | 354 |
| Cash | 17 | 26 | 326 | 102 |
| Total debt | 0 | 0 | 2 | 1 |
| Total liabilities | 125 | 240 | 12 | 14 |
| -106 | -123 | 470 | 340 | |
| 36 | 36 | 54 | 54 | |
| – | – | -13.0% | -37.1% | |
| 22.5% | 16.7% | -13.4% | -42.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -38 | -59 | -133 | |
| 0 | 0 | 1 | 0 | |
| -19 | -38 | -60 | -133 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 3 | 6 | 10 |
Valuation
- –
- –
- –
- 1.6×
- 68.7×
- –
- –
- -68.1%
- -73.2%
- 0.0%
Profitability
- 98.5%
- -5,618.8%
- -5,026.0%
- -5,170.7%
- -56.4%
- -4.0%
- -43.8%
- -49.3%
- -56.5%
- 4,442.3%
Growth
- +33.0%
- –
- −123.3%
- –
- +14.0%
Financial health
- -0.6×
- 0.00
- 0.4%
- –
- 23.14
- 23.14
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 948
Top 18%of 868
Bottom 1%of 985
What analysts expect
- Average price target
- $33.00
- Range
- $15.00 – $51.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.75 | -0.74 | −1.2% |
| Mar 26, 2026 | -0.79 | -0.73 | −8.2% |
| Nov 5, 2025 | -0.63 | -0.78 | +19.2% |
| Aug 6, 2025 | -0.74 | -0.61 | −21.3% |
| May 6, 2025 | -0.51 | -0.49 | −4.1% |
| Mar 13, 2025 | -1.59 | -0.56 | −183.9% |
| Nov 7, 2024 | -6.96 | -0.54 | −1,200.3% |
| Dec 31, 2023 | -0.14 | – | – |
News
FlexShares Morningstar Global Upstream Natural Resources Index Fund declares quarterly distribution of $0.3663Seeking Alpha · Sep 18, 2026The newest story we have is from Sep 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
60Pass
Philip Fisher
60Pass
Peter Lynch
100Pass
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
59No pass
Questions about Upstream Bio
Is Upstream Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Upstream Bio AI analysis
What does Upstream Bio do?
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. It is in Biotechnology.
Does Upstream Bio pay a dividend?
No. Upstream Bio does not pay a dividend at the moment.
Is Upstream Bio stock halal?
No. Upstream Bio does not pass our halal screen: its cash and confirmed interest-bearing investments are 52% of its market value, at or above the 33% limit. How we check
How has Upstream Bio stock done over the past year?
Down 84.4% over the past twelve months, to $3.58. It traded between $2.74 and $32.60 and is 89.0% below its high.
Who are Upstream Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Upstream Bio's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.